A Prognostic 14-Gene Expression Signature for Lung Adenocarcinoma: A Study Based on TCGA Data Mining

Figure 4

Correlation of RiskScore and survival rate (Kaplan-Meier curves) with clinicopathological staging characteristics. (a) Distribution of RiskScore in TNM stage. The by Kruskal-Wallis rank sum test. (b) Differences between the high-risk () and low-risk () groups in stage I patients were determined by the log-rank test (). Five-year overall survival was 35.6% (95% CI: 23.5%-53.8%) and 66.9% (95% CI: 55.8%-80.3%) for the high-risk and low-risk groups, respectively. (c) Differences between the high-risk () and low-risk () groups in stage II patients were determined by the log-rank test (). Five-year overall survival was 16.95% (95% CI: 7.09%-40.6%) and 53.1% (95% CI: 33.5%-84.2%) for the high-risk and low-risk groups, respectively. (d) Differences between the high-risk () and low-risk () groups in stage III patients were determined by the log-rank test (). Five-year overall survival was 6.31% (95% CI: 1.09%-36.5%) and 42.3% (95% CI: 20.2%-88.6%) for the high-risk and low-risk groups, respectively. (e) Distinct expression of each DEG between different clinicopathological stage samples.

(a)

(b)

(c)

(d)

(e)